2020 Endocrine Case Management: Meet the Professor

Endocrine Case Management: Meet the Professor is designed to provide physicians with a concise and high-quality review of 50 common and rare endocrine disorders to help you keep your practice current. It consists of case-based clinical cases and rationale by experts in all areas of endocrinology, diabetes, and metabolism.

You must first purchase this through our online store. Once you have completed your purchase you will receive access to this CME activity.

Visit the Online Store to purchase today.

Target Audience

Endocrine Case Management: Meet the Professor provides case-based education to clinicians interested in improving patient care.

Learning Objectives

Endocrine Case Management: Meet the Professor  will allow learners to assess their knowledge of all aspects of endocrinology, diabetes, and metabolism.

Upon completion of this educational activity, learners will be able to:

  • Recognize clinical manifestations of endocrine and metabolic disorders and select among current options for diagnosis, management, and therapy.
  • Identify risk factors for endocrine and metabolic disorders and develop strategies for prevention.
  • Evaluate endocrine and metabolic manifestations of systemic disorders.
  • Use existing resources pertaining to clinical guidelines and treatment recommendations for endocrine and related metabolic disorders to guide diagnosis and treatment.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Educator/Teacher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Quality Improvement and Healthcare Delivery
General Endocrinology
Hormone Abuse
Growth Disorders
Health Disparities
Hormones and Cancer
Men’s Health
Neuroendocrinology and Pituitary
Nutrition
Obesity
Pediatric Endocrinology
Surgery
Thyroid/HPT Axis
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 30.00 AMA PRA Category 1 Credits
  • 30.00 CME Certificate of Participation
Course opens: 
04/25/2020
Course expires: 
04/30/2023
Pricing: 
Non-Member
99.00 / e-book $79.00
Member
79.00 / e-book $59.00
In-Training Member
59.00 / e-book $39.00
Rating: 
0

2020 Meet-The-Professor Case Management Faculty

Craig A. Alter, MD
Children’s Hospital of Philadelphia

Bradley D. Anawalt, MD
University of Washington

Richard J. Auchus, MD, PhD
University of Michigan

Laura K. Bachrach, MD
Stanford Medical Center

Stephen G. Ball, PhD, FRCP
Royal Victoria Infirmary
United Kingdom

Irina Bancos, MD
Mayo Clinic – Rochester

Diana Barb, MD
University of Florida

Andrew J. Bauer, MD
The Children’s Hospital of Philadelphia

Petter Bjornstad, MD
University of Colorado School of Medicine

Kristien Boelaert, MD
University of Birmingham
United Kingdom

Elizabeth Buschur, MD
Ohio State University Medical Center

Marcelle I. Cedars, MD
University of California – San Francisco

Philippe Chanson, MD, MS
Paris-Saclay University Hospital
France

Marc-Andre Cornier, MD
University of Colorado School of Medicine

Mehul T. Dattani, MD, DCH, FRCPCH, FRCP, MBBS
UCL Institute of Child Health
United Kingdom

Chrysoula Dosiou, MD
Stanford University School of Medicine

Richard Eastell, MD, MBChB
University of Sheffield
United Kingdom

Rossella Elisei, MD
University of Pisa
Italy

Ghada El-Hajj Fuleihan, MD, MPH
American University of Beirut
Lebanon

Mary C. Frates, MD
Brigham and Women’s Hospital

Neil J. Gittoes, PhD, FRCP, MBCB, BSc
Centre for Endocrinology, Diabetes & Metabolism
Queen Elizabeth Hospital, University of Birmingham
United Kingdom

Whitney S. Goldner, MD
University of Nebraska Medical Center

Jennifer B. Green, MD
Duke University Medical Center

Ashley Grossman, MD, FRCP
Churchill Hospital
United Kingdom

Mathis Grossmann, MD, PhD, FRACP
University of Melbourne
Austin Health
Australia

Mark Gurnell, PhD, FRCP, MBBS, MA
University of Cambridge, Wellcome Trust
MRC Institute of Metabolic Science & School of Clinical Medicine
United Kingdom

Claire E. Higham, DPhil, MBBS
Christie Hospital
United Kingdom

Sacha J. Howell, PhD, FRCP
Manchester University
United Kingdom

Channa N. Jayasena, MD, PhD
Imperial College London
United Kingdom

Electron Kebebew, MD
Stanford University

Marta Korbonits, MD, PhD
Barts and the London School of Medicine
United Kingdom

Andrea L. Kossler, MD
Stanford University

E. Michael Lewiecki, MD
New Mexico Clinical Research & Osteoporosis Center

Matthew Lewis, MD, MPH
Stanford University

Lillian R. Meacham, MD
Emory University School of Medicine

Mark E. Molitch, MD
North Western University
Feinberg Medical School

Elizabeth J. Murphy, MD, DPhil
University of California – San Francisco
San Francisco General Hospital

Robert D. Murray, MD, FRCP, BSc
Leeds Teaching Hospital NHS Trust
United Kingdom

Rochelle N. Naylor, MD
University of Chicago

Genevieve S. Neal-Perry, MD, PhD
University of Washington

Simon H.S. Pearce, MD, FRCP, MBBS
Newcastle University
United Kingdom

Ian Reid, FRACP
University of Auckland
New Zealand

Molly O. Regelmann, MD
Children’s Hospital at Montefiore

Micol S. Rothman, MD
University of Colorado – Denver

Marzieh Salehi, MD, MS
University of Texas

David Saxon, MD, MSc
University of Colorado

Phyllis W. Speiser, MD 
Cohen Children’s Medical Center of New York
Northwell Health

Carole A. Spencer, PhD, FACB, MT
University of Southern California

Vin Tangpricha, MD, PhD
Emory University School of Medicine

Peter J. Tebben, MD
Mayo Clinic - Rochester

Christopher J. Thompson, MD, PhD 
Beaumont Hospital
RCSI Medical School

Jenny Tong, MD, MPH
Duke University

David J. Torpy, PhD, FRACP, MBBS
Royal Adelaide Hospital
Australia

Peter J. Trainer, MD, FRCP, MBChB, BSc
The Christie NHS Foundation Trust
United Kingdom

Greet Van Den Berghe, MD, PhD
Catholic University of Leuven
Belgium

Thomas Weber, MD
Duke University

Steven D. Wittlin, MD
University of Rochester School of Medicine and Dentistry

Joy Y. Wu, MD, PhD 
Stanford University School of Medicine

William F. Young, MD, MSc
Mayo Clinic – Rochester

Philip S. Zeitler, MD, PhD 
Children’s Hospital of Colorado
University of Colorado

ANNUAL MEETING STEERING COMMITTEE CLINICAL CHAIRS

Carolyn L. Smith, PhD – AMSC Chair
Senior Associate Dean, Baylor College of Medicine 

Maralyn Druce, MA, FRCP, PhD – Clinical Practice Chair
Queen Mary University of London

David A. D’Alessio, MD – Clinical Science Chair
Duke University School of Medicine 

Annual Meeting Steering Committee Clinical Peer Reviewers
Anders Juul, MD, PhD, DMSC; Antonio Bianco, MD, PhD; Bassil Kublaoui, MD, PhD; Daniel Dumesic, MD; David D’Alessio, MD; Dawn Davis, MD, PhD; Eliot Brinton, MD; Francesco Celi, MD, MHSc; Jennifer Sherr, MD, PhD; Jennifer Sipos, MD; Larry Fox, MD; Lauren Fishbein, MD, PhD; Margareta Pisarska, MD; Marie Demay, MD; Mark Cooper, MD, PhD; Matthew Freeby, MD; Nicola Napoli, MD, PhD; Niki Karavitaki, FRCP, PhD; Richard Feelders, MD, PhD; Robert Wermers, MD; Robin Peeters, MD, PhD; Selma Witchel, MD; Veronica Mericq, MD. 


STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Annual Meeting Steering Committee.  

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships as of January 1, 2019: The following faculty reported relevant financial relationships, as identified below, as of January 1, 2020: 
Craig A. Alter, MD,
Advisory Board Member; Self; Novo Nordisk. Consulting Fee; Self; Pfizer, Inc; Bradley D. Anawalt, MD, Self; Up to Date Author; Richard J. Auchus, MD, PhD, Consulting Fee; Self; Novartis Pharmaceuticals, Corcept Therapeutics, Jansen Pharmaceuticals, Adrenas Therapeutics, Selenity Therapeutics, Quest Diagnostics. Research Investigator; Self; Novartis Pharmaceuticals, Corcept Therapeutics, Strongbridge Biopharma, Neurocrine Biosciences, Spruce Biosciences; Irina Bancos, MD, Advisory Board Member; Self; Corcept; Andrew J. Bauer, MD, Other; Self; Sandoz; Petter M. Bjornstad, MD, Speaker; Self; Horizon Pharma. Other; Self; Boehringer Ingelheim; Philippe Chanson, MD, MS, Advisory Board Member; Self; Tiburio. Research Investigator; Self; Tiburio; Mehul T. Dattani, MD, DCH, FRCPCH, FRCP, MBBS, Advisory Board Member; Self; Novo Nordisk. Consulting Fee; Self; Ipsen. Speaker; Self; Novo Nordisk; Chrysoula Dosiou, MD, Advisory Board Member; Self; Horizon Therapeutics; Richard Eastell, MD, MBChB, Consulting Fee; Self; Roche Diagnostics, Immunodiagnostic Systems, Nittobo. Grant Recipient; Self; Roche Diagnostics, Immunodiagnostic Systems, Nittobo; Rossella Elisei, MD, Advisory Board Member; Self; Bayer, Inc., Loxo, Ipsen. Consulting Fee; Self; Genzyme Corporation, Eli Lilly & Company, Exelixis, Inc.; Neil J. Gittoes, PhD, FRCP, MBCB, BSc, Advisory Board Member; Self; Shire, Amgen Inc. Consulting Fee; Self; Shire, Takeda. Speaker; Self; Shire; Whitney S. Goldner, MD, Research Investigator; Self; Roche Diagnostics; Jennifer B. Green, MD, Advisory Board Member; Self; AstraZeneca, Boehringer Ingelheim. Consulting Fee; Self; Novo Nordisk. Research Investigator; Self; Boehringer Ingelheim, Sanofi; Mathis Grossmann, MD, PhD, FRACP, Speaker; Self; Besins Health Care; Mark Gurnell, PhD, FRCP, MBBS, MA, Speaker; Self; Ipsen; Channa N. Jayasena, MD, PhD, Speaker; Self; BES 2016: Speaking against motion for androgen therapy in older men, during debate sponsored by Besins healthcare; Marta Korbonits, MD, PhD, Advisory Board Member; Self; ONO-Pharma, Novo Nordisk. Research Investigator; Self; ONO-Pharma. Speaker; Self; Ipsen, Pfizer, Inc; Andrea L. Kossler, MD, Advisory Board Member; Self; Horizon Therapeutics; E. Michael Lewiecki, MD, Advisory Board Member; Self; Amgen Inc. Advisory Board Member; Spouse; Radius Health, Inc, Alexion Pharmaceuticals, Inc., Sandoz. Grant Recipient; Self; Amgen Inc, Radius Health, Inc. Speaker; Self; Alexion Pharmaceuticals, Inc., Radius Health, Inc; Mark E. Molitch, MD, Advisory Board Member; Self; Jansen Pharmaceuticals, Sanofi. Consulting Fee; Self; Merck, Novartis Pharmaceuticals, Pfizer, Inc.. Grant Recipient; Self; Novartis Pharmaceuticals, Bayer, Inc., Strongbridge, Novo Nordisk; Robert D. Murray, MD, FRCP, BSc, Grant Recipient; Self; Sandoz, Takeda, Pfizer, Inc; Simon H.S. Pearce, MD, FRCP, MBBS, Research Investigator; Self; Apitope. Speaker; Self; Sanofi-Aventis, Quidel; Ian Reid, FRACP, Advisory Board Member; Self; Amgen Inc. Research Investigator; Self; Amgen Inc. Speaker; Self; Eli Lilly & Company, Amgen Inc.; Molly O. Regelmann, MD, Consulting Fee; Self; Bluebird Bio. Speaker; Self; Bluebird Bio; Phyllis W. Speiser, MD, Advisory Board Member; Self; Spruce Biosciences. Consulting Fee; Self; Gerson Lehman Group. Research Investigator; Self; Boehringer Ingelheim. Speaker; Self; Peter J. Tebben, MD, Research Investigator; Self; Ultragenyx; Christopher J. Thompson, MD, PhD, Speaker; Self; Otsuka; Steven D. Wittlin, MD, Advisory Board Member; Self; Senseonics. Consulting Fee; Self; novo. Speaker; Self; Medtronic-Diabetes; Philip S. Zeitler, MD, PhD, Consulting Fee; Self; Merck, Eli Lilly & Company, Boehringer Ingelheim, Novo Nordisk. Research Investigator; Self; Jansen Pharmaceuticals.

The following faculty reported no relevant financial relationships as of January 1, 2020:
Stephen G. Ball, PhD, FRCP; Diana Barb, MD; Laura K. Bachrach, MD; Elizabeth Buschur, MD; Kristien Boelaert, MD; Marcelle I. Cedars, MD; Mary C. Frates, MD; Marc-Andre Cornier, MD; Ghada El-Hajj Fuleihan, MD, MPH; Ashley Grossman, MD, FRCP; Claire E. Higham, DPhil, MBBS; Sacha J. Howell, PhD, FRCP; Electron Kebebew, MD; Rochelle N. Naylor, MD; Genevieve S. Neal-Perry, MD, PhD; Elizabeth J. Murphy, MD, DPhil; Lillian R. Meacham, MD; Matthew Lewis, MD, MPH; Joy Y. Wu, MD, PhD; Carole A. Spencer, PhD, FACB, MT; Jenny Tong, MD, MPH; William F. Young, MD, MSc; Vin Tangpricha, MD, PhD; Peter J. Trainer, MD, FRCP, MBChB, BSc; David J. Torpy, PhD, FRACP, MBBS; Greet Van Den Berghe, MD, PhD; David Saxon, MD, MSc; Micol S. Rothman, MD; Thomas Weber, MD; Marzieh Salehi, MD, MS

The following AMSC peer reviewers reported relevant financial relationships as of January 1, 2020:
Anders Juul, MD, PhD, DMSC,
Novo Nordisk, Pfizer, Ferring, Merck, Bayer - Speakers bureau - honorarium ; Novo Nordisk, pharmaceutical industry - sponsor and PI of a clinical multicenter trial (NESGAS), unrestricted research grant; Ferring, pharmaceutical industry - Clinical co-investigator in a Ferring-sponsored clinical trial (PORIYA); Diurnal, pharmaceutical industry - Principal investigator in Denmark - Financial support for  participation in a multicenter study (RCT) on long-acting- hydrocortisone (Chronocort) in CAH; Antonio Bianco, MD, PhD, paid consultant for Allergan, BLA Technology, IBSA Foudnation, Synthonics; Daniel Dumesic, MD, NIH, Study Section member, per diem fee; NIH, P50 grantee, 10% FTE; David D’Alessio, MD, American Diabetes Association- Associate Editor for Diabetes and Diabetes Care; Lilly- consultant and research grant; Merck- research grant; Intarcia- consultant; Eliot Brinton, MD, Akcea--Advisor & speaker; Amarin--Advisor & speaker; Amgen--Advisor & speaker; Boehringer-Ingelheim--speaker; Esperion--Advisor; Kowa--Advisor & speaker; Medicure--Advisor; Merck--Advisor & speaker; Novo-Nordisk--speaker; Regeneron--Advisor & speaker; Sanofi-Aventis--Advisor & speaker; Francesco Celi, MD, MHSc, IBSA; Acella; Jennifer Sherr, MD, PhD, Medtronic Diabetes, Consultant; Bigfoot Biomedical, Advisory Board; Lilly, Advisory Board; Insulet, Advisory Board; JDRF, grantee; Cecelia Health, Advisory Board; Sanofi, Consultant; Marie Demay, MD, Syros Pharmaceuticals CMO, husband; NIH reviewer and grantee, self; Nicola Napoli, MD, PhD, UCB, LILLY: Advisory Board; Consulting fees: Abiogen, Lilly; Speaker Fee: Lilly; Richard Feelders, MD, PhD, Novartis: research grants; Ipsen: research grants; Robin Peeters, MD, PhD, Berlin-Chemie: Lecture fee; Goodlife Fertility BV, Lecture fee; Institut Biochimique SA (IBSA), Lecture fee; Sanofi Genzyme, Lecture fee, advisory board; Bayer, Lecture fee, advisory board; EISAI, advisory board; Veronica Mericq, MD, Grant of growth innovation (GGI grant) scientific committee member; Yearly Prize, funded by Merck; Scientific committee of EDGe; educational pediatric endocrinology activity funded by Novartis/Sandoz  since 2014; Pfizer global adisory board for SGA specific subject; Advisory board for Latinamerica based Sandoz, Merck and Novonordisk. 

The following AMSC peer reviewers reported no relevant financial relationships as of January 1, 2020:
Bassil Kublaoui, MD, PhD; Dawn Davis, MD, PhD; Jennifer Sipos, MD; Larry Fox, MD; Lauren Fishbein, MD, PhD; Margareta Pisarska, MD; Mark Cooper, MD, PhD; Matthew Freeby, MD; Niki Karavitaki, FRCP, PhD; Robert Wermers, MD; Selma Witchel, MD.

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:
The educational content in this enduring activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.  

DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.  

PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.  

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grant(s) or other funds from any commercial supporter. 

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this activity for a maximum of 30.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

METHOD OF PARTICIPATION
This enduring material is presented in print format. The estimated time to complete this activity, including review of material, is 30 hours. Participants must achieve a minimum score of 70% to claim CME credit. After initially completing the module, if participants do not achieve a minimum score of 70%, they have the option to change their answers and make additional attempts to achieve a passing score. Participants also have the option to clear all answers and start over.

AMA PRA CATEGORY 1 CREDIT (CME) INFORMATION
To receive a maximum of 30.0 AMA PRA Category 1 Credits™, participants must complete the online interactive module and activity evaluation located at https://education.endocrine.org/MTP2020. Participants must achieve a minimum score of 70% to claim CME credit. After initially completing the module, if participants do not achieve a minimum score of 70%, they have the option to change their answers and make additional attempts to achieve a passing score. Learners also have the option to clear all answers and start over.  

LAST REVIEW DATE: February 2020

ACTIVITY RELEASE DATE: April 6, 2020

ACTIVITY EXPIRATION DATE:
April 30, 2023 (date after which this enduring material is no longer certified for AMA PRA Category 1 Credits™)
For questions about content or obtaining CME credit, please contact the Endocrine Society at http://education.endocrine.org/contact.

Available Credit

  • 30.00 AMA PRA Category 1 Credits
  • 30.00 CME Certificate of Participation

You must first purchase this through our online store. Once you have completed your purchase you will receive access to this CME activity.

Visit the Online Store to purchase today.